Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam vs propofol in modified electroconvulsive therapy
jRCT1030240216Not yet recruiting
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of remimazolam in major depressive disorder (MDD) and schizophrenia (2 arms), sponsored by none. Primary endpoint: 4AT-J score immediately after mECT. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
remimazolam
03
Conditions
major depressive disorder (MDD)schizophrenia
Beyond the preview
Go deeper on jRCT1030240216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1030240216.